E-viri
Recenzirano
-
Yudkin, John S; Lehman, Richard; Krumholz, Harlan M
BMJ, 03/2011, Letnik: 342, Številka: 7797Journal Article
What has become apparent from the rosiglitazone saga is that the impact of newer glucose lowering agents on cardiovascular disease is impossible to predict from their effects on surrogate end points-something which also invalidates many of the conclusions from cost-benefit estimates. ...patients who have these drugs recommended should be told...
